Genmab (NASDAQ: GMAB) details progress of DKK 725m share buy-back program

Rhea-AI Filing Summary

Genmab A/S provides an update on its share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to cover Restricted Stock Unit commitments. From March 2 to March 6, 2026, the company repurchased 101,000 shares for a total of DKK 180,733,150, bringing total repurchases under the program to 249,000 shares at a total value of DKK 452,588,620. Genmab corrects a previously reported “Accumulated through last announcement” figure, which should have been 63,000 shares, resulting in a corrected accumulated figure of 148,000 shares. After these transactions, Genmab holds 2,766,533 treasury shares, equal to 4.31% of its total share capital and voting rights.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated March 9, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: March 9, 2026

Exhibit 99.1

Transactions in Connection with Share Buy-back Program

Company Announcement

COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program.

The share buy-back program is expected to be completed no later than March 31, 2026.

The following transactions were executed under the program from March 2 to March 6, 2026:

			No. of shares			Average price (DKK)						Total value (DKK)
Accumulated through last announcement*			148,000									271,855,470
March 2, 2026			15,000			1,865						27,971,250
March 3, 2026			23,000			1,793						41,241,300
March 4, 2026			20,000			1,787						35,749,200
March 5, 2026			20,000			1,788						35,769,800
March 6, 2026			23,000			1,739						40,001,600
Total			101,000									180,733,150
Accumulated under the program			249,000									452,588,620

* The “Accumulated through last announcement” figure previously communicated on March 2, 2026, was incorrectly stated as 1,431,958. The correct figure was 63,000 shares. Combined with subsequent purchases, this results in the corrected accumulated figure of 148,000 shares as stated above.

Following these transactions, Genmab holds 2,766,533 shares as treasury shares, corresponding to 4.31% of the total share capital and voting rights.

The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 05 dated February 17, 2026.

About Genmab

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit

Genmab.com  and follow us on LinkedIn and X.

Contact:

Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 15 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Transactions in Connection with Share Buy-back Program

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 15 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Transactions in Connection with Share Buy-back Program

The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 15 Page 3/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

FAQ

What share buy-back program did Genmab (GMAB) update in this 6-K?

Genmab updated investors on a share buy-back program initiated February 17, 2026, to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million, intended to honor commitments under its Restricted Stock Unit program.

How many Genmab (GMAB) shares were repurchased between March 2 and March 6, 2026?

Between March 2 and March 6, 2026, Genmab repurchased 101,000 shares under its buy-back program. These purchases were made at average prices around DKK 1,739–1,865 per share, for a combined total value of DKK 180,733,150 during that period.

What is the total volume and value repurchased so far in Genmab’s buy-back program?

Under the program, Genmab has repurchased a total of 249,000 shares for an aggregate value of DKK 452,588,620. This cumulative figure reflects purchases made since the program’s start, including the transactions executed from March 2 to March 6, 2026.

What correction did Genmab (GMAB) make to its previously reported buy-back figures?

Genmab corrected its earlier “Accumulated through last announcement” figure. It was previously communicated as 1,431,958 shares, but the correct number was 63,000 shares. Including subsequent purchases, the corrected accumulated figure is now 148,000 shares under the program.

How many treasury shares does Genmab (GMAB) now hold after the latest repurchases?

Following the recent buy-back transactions, Genmab holds 2,766,533 shares as treasury shares. This position corresponds to 4.31% of the company’s total share capital and voting rights, reflecting the cumulative impact of the share repurchase activities to date.

When is Genmab’s share buy-back program expected to be completed?

The share buy-back program is expected to be completed no later than March 31, 2026. This timeline was set when the program was announced and frames the period during which Genmab may continue repurchasing shares within the approved limits.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 31.4 KB